早期应用替罗非班对老年急性冠脉综合征患者PCI术后的影响

Effect of early application of Tirofiban after PCI for elderly patients with acute coronary syndrome

目的探讨早期应用替罗非班在老年急性冠脉综合征(ACS)患者中的疗效和安全性。方法收集我院110例老年ACS患者,按照随机化原则分为对照组(常规治疗,55例)和观察组(常规治疗+替罗非班,55例),对照组急诊行冠状动脉介入手术(PCI)和常规治疗,观察组在对照组基础上早期应用替罗非班治疗,比较两组血小板聚集率、术后不良心血管事件发生率及术后心功能变化。结果两组血小板聚集率术前比较差异无统计学意义(P>0.05),术后72h比较差异具有统计学意义(P<0.05);对照组术后12周内不良心血管事件发生率明显高于观察组,差异具有统计学意义(P<0.05);两组心功能指标术后1周差异无统计学意义(P>0.05),术后12周比较差异具有统计学意义(P<0.05)。结论在老年ACS患者行PCI及常规治疗基础上早期应用替罗非班治疗,可显著降低血小板聚集率和不良心血管事件发生率,改善患者的心脏功能,推荐临床应用。

Objective To discuss the clinical efficacy and safety of early application of Tirofiban after PCI for elderly patients with acute coronary syndrome. Methods 110 eider patients with acute coronary syndrome（ACS） in our hospital were collected and divided into the control group （routine treatment, 55 eases） and the observation group （routine treatment＋ Tirofiban, 55 cases）. The observation group was given Tirofiban on the foundation of the control group. Compared the differences of platelet aggregation rate, major adverse cardiac events （MACEs） and cardiac function between the two groups. Results There was no significant difference in platelet aggregation rate between the two groups （P〉0.05）, but there was significant difference in 72h after PCI （P〈0.05） ; MACEs of the control group was significantly higher than the observation group in 12 weeks （P〈0.05） ; there was no significant difference in the index of cardiac function between the two groups in 1 week after PCI （P〉 0.05）, but there were significant differences in 12 weeks after PCI （P〈0.05）. Conclusion For elder ACS patients, applied Tirofiban on the foundation of routine treatment can reduce platelet aggregation rate, incidence of MACEs and improve cardiac function, it is worthy to recommend for clinical treatment.